{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:01:07Z","timestamp":1791594067296,"version":"4.3.4"},"reference-count":82,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T00:00:00Z","timestamp":1595635200000},"content-version":"vor","delay-in-days":390,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA188298"],"award-info":[{"award-number":["R01CA188298"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA233975"],"award-info":[{"award-number":["R01CA233975"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA229766"],"award-info":[{"award-number":["R01CA229766"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA194389"],"award-info":[{"award-number":["U01CA194389"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R25CA180993"],"award-info":[{"award-number":["R25CA180993"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001021","name":"Damon Runyon Cancer Research Foundation","doi-asserted-by":"publisher","award":["DR-CI#71-14"],"award-info":[{"award-number":["DR-CI#71-14"]}],"id":[{"id":"10.13039\/100001021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001021","name":"Damon Runyon Cancer Research Foundation","doi-asserted-by":"publisher","award":["PST#09-16"],"award-info":[{"award-number":["PST#09-16"]}],"id":[{"id":"10.13039\/100001021","id-type":"DOI","asserted-by":"publisher"}]},{"name":"American Society of Hematology Scholar Award"},{"name":"V Foundation for Cancer Research Abeloff Scholar Award"},{"name":"Conquer Cancer Foundation of the American Society of Clinical Oncology Young Investigator Award"},{"name":"Stinehart\/Reed Award"},{"name":"Shanahan Family Fund"},{"name":"NIH Director\u2019s New Innovator Award Program","award":["1-DP2-CA186569"],"award-info":[{"award-number":["1-DP2-CA186569"]}]},{"DOI":"10.13039\/100009729","name":"Ludwig Institute for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009729","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.cell.2019.06.011","type":"journal-article","created":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T10:30:27Z","timestamp":1562236227000},"page":"699-713.e19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":219,"title":["Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction"],"prefix":"10.1016","volume":"178","author":[{"given":"David M.","family":"Kurtz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad S.","family":"Esfahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Scherer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Soo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih Long","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron M.","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"D\u00fchrsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"H\u00fcttmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Casasnovas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason R.","family":"Westin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthais","family":"Ritgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"B\u00f6ttcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton W.","family":"Langerak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Roschewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wyndham H.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Gaidano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmin","family":"Bahlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hallek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Tibshirani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Diehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ash A.","family":"Alizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cell.2019.06.011_bib1","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.cell.2019.06.011_bib2","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1200\/JCO.2015.63.3651","article-title":"Biomarker: Predictive or Prognostic?","volume":"33","author":"Ballman","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.cell.2019.06.011_bib3","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.cell.2019.06.011_bib4","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nature12627","article-title":"Tumour heterogeneity in the clinic","volume":"501","author":"Bedard","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.cell.2019.06.011_bib5","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2011.36.9348","article-title":"Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial","volume":"30","author":"B\u00f6ttcher","year":"2012","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.cell.2019.06.011_bib6","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2967\/jnumed.110.082586","article-title":"18F-FDG PET\/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation","volume":"52","author":"Cashen","year":"2011","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.cell.2019.06.011_bib7","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1158\/2159-8290.CD-17-0716","article-title":"Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling","volume":"7","author":"Chaudhuri","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cell.2019.06.011_bib8","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1287\/mnsc.1080.0872","article-title":"Modeling a Presidential Prediction Market","volume":"54","author":"Chen","year":"2008","journal-title":"Manage. Sci."},{"key":"10.1016\/j.cell.2019.06.011_bib9","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.cell.2019.06.011_bib10","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/annonc\/mdv594","article-title":"A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel","volume":"27","author":"Chi","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cell.2019.06.011_bib11","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S1470-2045(17)30444-8","article-title":"Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study","volume":"18","author":"Chiappella","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cell.2019.06.011_bib12","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","article-title":"Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12","volume":"32","author":"Crump","year":"2014","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.cell.2019.06.011_bib13","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature10983","article-title":"The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups","volume":"486","author":"Curtis","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.cell.2019.06.011_bib14","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood.V124.21.391.391","article-title":"Positron Emission Tomography (PET) Guided Therapy of Aggressive Lymphomas \u2013 a Randomized Controlled Trial Comparing Different Treatment Approaches Based on Interim PET Results (PETAL Trial)","volume":"124","author":"Duehrsen","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.cell.2019.06.011_bib15","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2017.76.8093","article-title":"Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial","volume":"36","author":"D\u00fchrsen","year":"2018","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.cell.2019.06.011_bib16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(17)30777-5","article-title":"Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials","volume":"19","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cell.2019.06.011_bib17","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","article-title":"The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM","volume":"17","author":"Edge","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.cell.2019.06.011_bib18","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cell.2019.06.011_bib19","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1200\/JCO.2015.62.0229","article-title":"Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish-Swedish Population-Based Study","volume":"33","author":"El-Galaly","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.cell.2019.06.011_bib20","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s10549-011-1895-2","article-title":"Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007\/150012; ACRIN 6657)","volume":"132","author":"Esserman","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.cell.2019.06.011_bib21","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/leu.2013.190","article-title":"Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab","volume":"27","author":"Fink","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.cell.2019.06.011_bib22","doi-asserted-by":"crossref","first-page":"e475","DOI":"10.1016\/S2352-3026(17)30171-0","article-title":"Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study","volume":"4","author":"Fink","year":"2017","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.cell.2019.06.011_bib23","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev.publhealth.20.1.145","article-title":"Time-dependent covariates in the Cox proportional-hazards regression model","volume":"20","author":"Fisher","year":"1999","journal-title":"Annu. Rev. Public Health"},{"key":"10.1016\/j.cell.2019.06.011_bib24","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1002\/sim.4322","article-title":"Subgroup identification from randomized clinical trial data","volume":"30","author":"Foster","year":"2011","journal-title":"Stat. Med."},{"key":"10.1016\/j.cell.2019.06.011_bib25","doi-asserted-by":"crossref","first-page":"302ra133","DOI":"10.1126\/scitranslmed.aab0021","article-title":"Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer","volume":"7","author":"Garcia-Murillas","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cell.2019.06.011_bib26","series-title":"Bayesian Data Analysis","author":"Gelman","year":"2014"},{"key":"10.1016\/j.cell.2019.06.011_bib27","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2019.06.011_bib28","doi-asserted-by":"crossref","first-page":"310","DOI":"10.6004\/jnccn.2018.0012","article-title":"Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology","volume":"16","author":"Gradishar","year":"2018","journal-title":"J.\u00a0Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.cell.2019.06.011_bib29","series-title":"A report of the natural duration of cancer","author":"Greenwood","year":"1926"},{"key":"10.1016\/j.cell.2019.06.011_bib30","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1001\/jamaoncol.2017.1007","article-title":"Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial","volume":"3","author":"Hahnen","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.cell.2019.06.011_bib31","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cell.2019.06.011_bib32","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood-2002-12-3837","article-title":"Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma","volume":"102","author":"Hamlin","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.cell.2019.06.011_bib33","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1001\/jama.2011.593","article-title":"A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer","volume":"305","author":"Hatzis","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.cell.2019.06.011_bib34","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.0006-341X.2000.00337.x","article-title":"Time-dependent ROC curves for censored survival data and a diagnostic marker","volume":"56","author":"Heagerty","year":"2000","journal-title":"Biometrics"},{"key":"10.1016\/j.cell.2019.06.011_bib35","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3324\/haematol.2016.154039","article-title":"Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14","volume":"102","author":"Hertzberg","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.cell.2019.06.011_bib36","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2016.0117","article-title":"NCCN Guidelines Insights: Non-Hodgkin\u2019s Lymphomas, Version 3.2016","volume":"14","author":"Horwitz","year":"2016","journal-title":"J.\u00a0Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.cell.2019.06.011_bib37","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/jnci\/djy076","article-title":"Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab\/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy","volume":"111","author":"Ignatiadis","year":"2019","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.cell.2019.06.011_bib38","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cell.2019.06.011_bib39","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma","volume":"329","year":"1993","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2019.06.011_bib40","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular Minimal Residual Disease in Acute Myeloid Leukemia","volume":"378","author":"Jongen-Lavrencic","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2019.06.011_bib41","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1200\/JCO.2016.67.1305","article-title":"Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group","volume":"34","author":"Kovacs","year":"2016","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.cell.2019.06.011_bib42","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.cell.2019.06.011_bib43","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1182\/blood-2016-05-714162","article-title":"Minimal residual disease is an independent predictor for 10-year survival in CLL","volume":"128","author":"Kwok","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.cell.2019.06.011_bib44","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1080\/01621459.2012.737735","article-title":"Dynamic Bayesian Forecasting of Presidential Elections in the States","volume":"108","author":"Linzer","year":"2013","journal-title":"J.\u00a0Am. Stat. Assoc."},{"key":"10.1016\/j.cell.2019.06.011_bib45","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1056\/NEJMsr1203730","article-title":"The prevention and treatment of missing data in clinical trials","volume":"367","author":"Little","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2019.06.011_bib46","first-page":"197","article-title":"Using random forests to estimate win probability before each play of an NFL game","volume":"10","author":"Lock","year":"2014","journal-title":"J.\u00a0Quant. Anal. Sports"},{"key":"10.1016\/j.cell.2019.06.011_bib47","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2019.06.011_bib48","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","article-title":"Event-free survival at 24\u00a0months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"32","author":"Maurer","year":"2014","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.cell.2019.06.011_bib49","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1182\/blood-2011-02-336990","article-title":"Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma","volume":"118","author":"Micallef","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cell.2019.06.011_bib50","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/sj.bmt.1701624","article-title":"The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma","volume":"23","author":"Moskowitz","year":"1999","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.cell.2019.06.011_bib51","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1200\/JCO.2009.26.5942","article-title":"Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma","volume":"28","author":"Moskowitz","year":"2010","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.cell.2019.06.011_bib52","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2019.06.011_bib53","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3109\/10428194.2013.831848","article-title":"Quantitative and qualitative analysis of metabolic response at interim positron emission tomography scan combined with International Prognostic Index is highly predictive of outcome in diffuse large B-cell lymphoma","volume":"55","author":"Nols","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.cell.2019.06.011_bib54","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2217\/fon-2016-0130","article-title":"ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma","volume":"12","author":"Nowakowski","year":"2016","journal-title":"Future Oncol."},{"key":"10.1016\/j.cell.2019.06.011_bib55","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/2040620715614529","article-title":"Monitoring minimal residual disease in acute myeloid leukaemia: a review of the current evolving strategies","volume":"7","author":"Ommen","year":"2016","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.cell.2019.06.011_bib56","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.cell.2019.06.011_bib57","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1515\/CCLM.2010.340","article-title":"Statistical methods for assessment of added usefulness of new biomarkers","volume":"48","author":"Pencina","year":"2010","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.cell.2019.06.011_bib58","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2019.06.011_bib59","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1182\/blood-2011-06-359943","article-title":"Interim 18-FDG-PET\/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP","volume":"119","author":"Pregno","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.cell.2019.06.011_bib60","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2019.06.011_bib61","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2019.06.011_bib62","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1200\/JCO.2011.38.2648","article-title":"Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab","volume":"30","author":"Safar","year":"2012","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.cell.2019.06.011_bib63","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1634\/theoncologist.2017-0177","article-title":"The Search for Surrogate Endpoints in Trials in Diffuse Large B-Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project","volume":"22","author":"Sargent","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.cell.2019.06.011_bib64","doi-asserted-by":"crossref","first-page":"364ra155","DOI":"10.1126\/scitranslmed.aai8545","article-title":"Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA","volume":"8","author":"Scherer","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cell.2019.06.011_bib65","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nrc3066","article-title":"Cell-free nucleic acids as biomarkers in cancer patients","volume":"11","author":"Schwarzenbach","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cell.2019.06.011_bib66","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1200\/JCO.2014.60.2383","article-title":"Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies","volume":"33","author":"Scott","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.cell.2019.06.011_bib67","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.cell.2019.06.011_bib68","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.cell.2019.06.011_bib69","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1056\/NEJMoa1510764","article-title":"Prospective Validation of a 21-Gene Expression Assay in Breast Cancer","volume":"373","author":"Sparano","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2019.06.011_bib70","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/00031305.1991.10475798","article-title":"On the Probability of Winning a Football Game","volume":"45","author":"Stern","year":"1991","journal-title":"Am. Stat."},{"key":"10.1016\/j.cell.2019.06.011_bib71","series-title":"Clinical prediction models: a practical approach to development, validation, and updating","author":"Steyerberg","year":"2009"},{"key":"10.1016\/j.cell.2019.06.011_bib72","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/EDE.0b013e3181c30fb2","article-title":"Assessing the performance of prediction models: a framework for traditional and novel measures","volume":"21","author":"Steyerberg","year":"2010","journal-title":"Epidemiology"},{"key":"10.1016\/j.cell.2019.06.011_bib73","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa1301077","article-title":"Autologous transplantation as consolidation for aggressive non-Hodgkin\u2019s lymphoma","volume":"369","author":"Stiff","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2019.06.011_bib74","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","article-title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","volume":"25","author":"Symmans","year":"2007","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.cell.2019.06.011_bib75","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1200\/JCO.2015.63.1010","article-title":"Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype","volume":"35","author":"Symmans","year":"2017","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.cell.2019.06.011_bib76","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1200\/JCO.2014.55.7561","article-title":"Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma","volume":"32","author":"Thompson","year":"2014","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.cell.2019.06.011_bib77","doi-asserted-by":"crossref","first-page":"346ra92","DOI":"10.1126\/scitranslmed.aaf6219","article-title":"Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer","volume":"8","author":"Tie","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cell.2019.06.011_bib78","doi-asserted-by":"crossref","first-page":"293","DOI":"10.6004\/jnccn.2017.0030","article-title":"NCCN Guidelines Insights: Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma, Version 1.2017","volume":"15","author":"Wierda","year":"2017","journal-title":"J.\u00a0Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.cell.2019.06.011_bib79","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.ejca.2010.12.027","article-title":"Prognostic significance of interim 18F-FDG PET\/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma","volume":"47","author":"Yang","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.cell.2019.06.011_bib80","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00277-010-1135-6","article-title":"Limited role of interim PET\/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"90","author":"Yoo","year":"2011","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.cell.2019.06.011_bib81","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1200\/JCO.2009.26.2493","article-title":"Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era","volume":"28","author":"Ziepert","year":"2010","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.cell.2019.06.011_bib82","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/cncr.25579","article-title":"Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma","volume":"117","author":"Zinzani","year":"2011","journal-title":"Cancer"}],"container-title":["Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0092867419306397?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0092867419306397?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T11:39:31Z","timestamp":1758800371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0092867419306397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":82,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0092867419306397"],"URL":"https:\/\/doi.org\/10.1016\/j.cell.2019.06.011","relation":{},"ISSN":["0092-8674"],"issn-type":[{"value":"0092-8674","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction","name":"articletitle","label":"Article Title"},{"value":"Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cell.2019.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}